menu
    • menu
    [{"orgOrder":0,"company":"Opna Bio","sponsor":"Longitude Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Opna Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Opna Bio \/ Longitude Capital","highestDevelopmentStatusID":"2","companyTruncated":"Opna Bio \/ Longitude Capital"},{"orgOrder":0,"company":"Opna Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"OPN-6602","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Opna Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Opna Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Opna Bio \/ Not Applicable"},{"orgOrder":0,"company":"Opna Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"OPN-2853","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Opna Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Opna Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Opna Bio \/ Not Applicable"},{"orgOrder":0,"company":"Opna Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"OPN-6602","moa":"||EP300\/CBP bromodomain","graph1":"Oncology","graph2":"Phase I","graph3":"Opna Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Opna Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Opna Bio \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Opna Bio

    Menu

    Opna Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Opna Bio

                            Switzerland arrow
                            PharmScience R&D
                            Not Confirmed

                            Opna Bio

                            Switzerland arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OPN-6602,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Opna Bio’s OPN-6602 Gets Orphan Drug Status for Multiple Myeloma

                            Details : OPN-6602 is a potent and selective EP300/CBP bromodomain inhibitor, which is currenty being evaluated for the treatment of relapsed or refractory multiple myeloma.

                            Product Name : OPN-6602

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 12, 2025

                            Lead Product(s) : OPN-6602,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Opna Bio

                            Switzerland arrow
                            PharmScience R&D
                            Not Confirmed

                            Opna Bio

                            Switzerland arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OPN-2853,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Opna Bio Shares Phase 1 Interim Data of OPN-2853 with Ruxolitinib in Myelofibrosis

                            Details : OPN-2853, a small molecule bromodomain and extra-terminal motif (BET) inhibitor, is being evaluated in combination with for treating intermediate-2 or high risk myelofibrosis.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 09, 2024

                            Lead Product(s) : OPN-2853,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Opna Bio

                            Switzerland arrow
                            PharmScience R&D
                            Not Confirmed

                            Opna Bio

                            Switzerland arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OPN-6602,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Opna Bio Doses First Patient in Phase 1 Multiple Myeloma Study of OPN-6602

                            Details : OPN-6602 is a potent and selective EP300/CBP bromodomain inhibitor, which is currenty being evaluated for the treatment of relapsed or refractory multiple myeloma.

                            Product Name : OPN-6602

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 26, 2024

                            Lead Product(s) : OPN-6602,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Opna Bio

                            Switzerland arrow
                            PharmScience R&D
                            Not Confirmed

                            Opna Bio

                            Switzerland arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Longitude Capital

                            Deal Size : $38.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Opna Bio Launches with $38 Million Series A Financing to Advance Novel Oncology Discovery Program and Diversif...

                            Details : The proceeds will be used to develop novel fragile-X mental retardation protein (FMRP) inhibitors in oncology as well as a diverse portfolio of clinical and preclinical oncology programs acquired from Plexxikon Inc.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 21, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Longitude Capital

                            Deal Size : $38.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth